- Home
- LVTX vs RADX Comparison
LVTX vs RADX Comparison
Compare LVTX & RADX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LVTX
- RADX
- Stock Information
- Founded
- LVTX 2016
- RADX 2021
- Country
- LVTX Netherlands
- RADX Australia
- Employees
- LVTX N/A
- RADX N/A
- Industry
- LVTX Biotechnology: Pharmaceutical Preparations
- RADX
- Sector
- LVTX Health Care
- RADX
- Exchange
- LVTX Nasdaq
- RADX NYSE
- Market Cap
- LVTX 33.9M
- RADX 32.5M
- IPO Year
- LVTX 2021
- RADX N/A
- Fundamental
- Price
- LVTX $1.31
- RADX $4.60
- Analyst Decision
- LVTX Hold
- RADX Strong Buy
- Analyst Count
- LVTX 3
- RADX 2
- Target Price
- LVTX $1.75
- RADX $13.50
- AVG Volume (30 Days)
- LVTX 39.1K
- RADX 22.6K
- Earning Date
- LVTX 08-19-2025
- RADX 02-26-2025
- Dividend Yield
- LVTX N/A
- RADX N/A
- EPS Growth
- LVTX N/A
- RADX N/A
- EPS
- LVTX N/A
- RADX N/A
- Revenue
- LVTX $4,990,000.00
- RADX $204,609.00
- Revenue This Year
- LVTX N/A
- RADX N/A
- Revenue Next Year
- LVTX N/A
- RADX N/A
- P/E Ratio
- LVTX N/A
- RADX N/A
- Revenue Growth
- LVTX N/A
- RADX N/A
- 52 Week Low
- LVTX $0.85
- RADX $3.50
- 52 Week High
- LVTX $2.39
- RADX $50.82
- Technical
- Relative Strength Index (RSI)
- LVTX 51.02
- RADX N/A
- Support Level
- LVTX $1.28
- RADX N/A
- Resistance Level
- LVTX $1.40
- RADX N/A
- Average True Range (ATR)
- LVTX 0.05
- RADX 0.00
- MACD
- LVTX -0.00
- RADX 0.00
- Stochastic Oscillator
- LVTX 52.63
- RADX 0.00
About LVTX LAVA Therapeutics N.V.
LAVA Therapeutics NV isa clinical stage immuno-oncology company. It is focused on transforming cancer treatment by developing a platform to selectively induce bispecific antibody utilizing the Gammabody platform for an undisclosed tumor associated antigen for the treatment of cancer. Company's pipeline include's products such as LAVA-1266, LAVA-1427, LAVA-1433, LAVA-1207, PF08046052, JNJ89853413.
About RADX RADIOPHARM THERANOSTICS LIMITED SPON ADS EACH REP 300 ORD
Radiopharm Theranostics Ltd is an Australian based clinical-stage radiotherapeutics company which is targeting cancer. The company has a pipeline of around four licensed platform technologies, with diagnostic and therapeutic applications in both pre-clinical and clinical stages of development. The company is engaged in research, development and commercialization of health technologies.